Aclaris Therapeutics

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aclaris Therapeutics reports Q1 earnings, highlights ATI-450 trial results

Aclaris Therapeutics reported financial highlights, discussed trial results for ATI-450, and highlighted optimism about its pipeline.
Strengths include targeted PD inhibition in HS study, competitive landscape discussions in atopic dermatitis, and changes in inclusion criteria for studies.
Challenges involve CNS adverse events in HS study, enrollment hurdles in psoriatic arthritis trial, and scrutiny on CK elevations and comparisons to other therapies.
Opportunities lie in potential value creation in immune-inflammatory diseases, market positioning in atopic dermatitis, and patient engagement strategies in RA and PSA studies.

Aclaris Therapeutics progresses ATI-2138 for atopic dermatitis, eyes growth

Aclaris Therapeutics is focused on advancing ATI-2138 for atopic dermatitis with a strong financial position. While facing questions on various fronts, the company's strategic direction and commitment to innovation offer promising opportunities for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.

Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO

Though data from a mid-stage study shows that treatment with Aclaris' (ACRS) JAK inhibitor met its primary endpoint, it also displays a greater-than-expected placebo effect.

Aclaris (ACRS) Down 21% on Mixed Results From Eczema Study

Aclaris Therapeutics shares plunged more than 24% Wednesday after the company's mild to severe atopic dermatitis (AD) treatment received disappointing topline results.  The results from the 4-week Phase 2b trial of its ATI-1777 treatment were not statistically superior to the Phase 2a trial, according to chairman Neal Walker added.

Aclaris Therapeutics shares torpedo on underwhelming dermatitis trial results

- ATI-1777 2% BID Achieved a Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 - - Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor Approach - - ATI-1777 Was Well Tolerated - WAYNE, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced top-line results from its Phase 2b study of ATI-1777, an investigational topical “soft” JAK 1/3 inhibitor, in patients with mild to severe atopic dermatitis (AD) (ATI-1777-AD-202; NCT05432596).

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

- ATI-1777 Phase 2a Trial Results Published in JID Innovations - - ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 - - Aclaris Announces Reduction in Workforce -

Aclaris Therapeutics Provides Corporate Update

Checkpoint Therapeutics

G1 Therapeutics

2Seventy Bio

Penny stocks, securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks requires research as their prices fluctuate wildly around key events.

Best Penny Stocks To Buy? 4 To Watch With Big News This Week

Ardelyx

Oatly

Phio Pharmaceuticals Corp

Rent the Runway

Penny stocks, defined as those trading under $5 per share, offer unique opportunities. With low prices and the potential for high percentage returns, it's understandable why penny stocks attract interest from new traders.

Penny Stocks To Buy Now? 5 Under $5 To Watch This Week

WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma).

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)

Aclaris (ACRS) decides to stop the development of its lead drug after top-line data from a mid-stage study did not achieve any study goals. Shares plunge 86% following the news.

Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study

Aclaris Therapeutics shares fell almost 90% after the biopharmaceutical company announced it is no longer continuing with the development of its rheumatoid arthritis therapeutic zunsemetinib. The company said that its Phase 2b study of zunsemetinib did not meet its primary or secondary endpoints as there was no notable differentiation between zunsemetinib and placebo across any measures of efficacy after 12 weeks.

Aclaris Therapeutics pulls arthritis drug research program; shares plummet

Aclaris Therapeutics on Monday said it would stop development of its rheumatoid arthritis treatment after it failed in a mid-stage trial.

Aclaris Therapeutics to stop development of rheumatoid arthritis drug

— Study Did Not Meet Primary or Secondary Efficacy Endpoints in Rheumatoid Arthritis — — Efficacy Results Do Not Support Further Development of Zunsemetinib — — Company to Host Conference Call and Webcast Today at 8:00 AM ET — WAYNE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced top-line results from a Phase 2b study of zunsemetinib (ATI-450), an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis (RA; ATI-450-RA-202).

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

- Topline Data from Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis Expected this Month – - Completion of Enrollment in ATI-1777 Phase 2b Trial in Atopic Dermatitis As Previously Announced; Topline Data Anticipated Around Year-End 2023 - WAYNE, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2023 and provided a corporate update.

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

- Top-line Data Anticipated Around Year End WAYNE, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of enrollment into ATI-1777-AD-202, its Phase 2b trial of its investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor, ATI-1777, in patients with mild to severe atopic dermatitis.

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Aclaris Therapeutics is a developer of kinome-based medicines for immune-inflammatory and oncology indications. The company's platform, KINect, helps advance small molecules targeting kinases to replicate or improve the effects of expensive biologics. ACRS has a lead asset, zunsemetinib, in phase 2 trials for rheumatoid arthritis and psoriatic arthritis, with other assets in early stages.

Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer

WAYNE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 10:30 AM ET, in New York, NY.

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

– Preliminary Data Support Progression to Phase 2a Proof of Concept Trials in T cell-mediated Autoimmune Diseases –

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

An analyst raised his price target on the biotech. He also maintained his buy recommendation on the stock.

Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday

- Completion of Enrollment in Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis As Previously Announced; Data Expected in Q4 2023 -

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Aclaris Therapeutics, Inc. results from a phase 2b study using zunsemetinib for the treatment of patients with rheumatoid arthritis are expected to be released by Q4 of 2023. The global rheumatoid arthritis market is expected to reach $33.3 billion by 2030. Results from the phase 2a study using zunsemetinib for the treatment of patients with psoriatic arthritis are expected to be released by the 1st half of 2024.

Aclaris Therapeutics: Q4 Of 2023 Catalyst Makes This A Must Watch

Agenus

Low-priced stocks tend to be more trouble than they are worth. On the rare occasion, however, these equities can turn out to be diamonds in the rough.

2 Low-Priced Stocks That Could Make You Richer

The biotech has completed enrollment in the next phase of an important development program. It is aiming to get a rheumatoid arthritis drug to market.

Why Aclaris Therapeutics Topped the Market on Tuesday

- Topline Data Anticipated in Q4 2023 WAYNE, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of enrollment into ATI-450-RA-202, its Phase 2b trial of oral zunsemetinib in patients with moderate to severe rheumatoid arthritis (RA).

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)

News for Aclaris Therapeutics Stock (ACRS)